Seisheng Pharmaceuticals shares climbed more than 160 percent, the vaccine did not promote shareholders busy sell-off, net profit-selling fund-raising project stalled.

Guide: The year's gain of 163.69 percent may be just beginningfour-board-up-racing pharmaceutical (300485SZ), after shareholders reduced their holdings and received a letter of concern from The Shenzhen Stock Exchange, finally strainedopened on June 18th, and the shares of Seisheng Pharmaceuticals continued to weaken, eventually closing down 6.76 per centBut the decline may have just begun, compared with the 163.69 per cent increase this yearfrequently disclose sing-up information on the new crown vaccinethe share price soaring major shareholders to cash out more than 400 million yuanon the evening of June 16, Saisheng Pharmaceuticals issued a notice that the company received three shareholders of Mary, Liu Shuqin, Kong Shuangquan issued a "share reduction plan notice letter."the total number of shares of the Company, or 3.4017% of the company's total, is expected to exceed about 16.47 million shares, or 3.4017% of the total number of shares, within six months from the date of the announcementthe three shareholders of Ma Li, Liu Shuqin and Kong Shuangquan gave the reasons for their own capital needs, of which Mary reduced its holdings accounted for 2.7948% of the company's total share capitalMary is the director, deputy general manager and finance director of Saisheng PharmaceuticalsPublic information shows that Maand Mary for brother and sister relationship, Liu Shuqin for Maand Mary's motheras of the date of disclosure of the announcement, Mary and his co-action officer Liu Shuqin and senior manager Kong Shuangquan held about 54.13 million shares, 11.66 million shares and 90,000 shares, respectively, accounting for 11.1792 percent of the total share capital, 2.4091 percent and 0.0186%this is not the first time That Mary and her concerted activists have reduced their holdingsJune 19, 2019, Mary and her acting man, Liu Shuqin, announced plans to reduce their holdings As of September 27th, Mary reduced her holdings by about 2.8982 million shares through centralized bidding at 9.415 yuan/share price-10.161 yuan/share, and Liu Shuqin reduced her stake by 3.88million shares at an average price of 9.02 yuan/share through a large-scale transaction the reduction, Mary and his concerted action man Liu Shuqin totaled 64.1237 million yuan it's worth noting that, in terms of share prices, the shares of Seisheng Pharmaceuticals have continued to fall since May 2018, while the performance has fallen significantly, and there is no sign of a reduction in Mary's holdings or related to it However, after entering the 2020 Lunar New Year, the pharmaceutical manufacturing industry is a group of seissy pharmaceutical stocks continued to rise, the year has risen as high as 163.69 percent Global Financial Statement notes that since February, Saisheng Pharmaceuticals has repeatedly said in The Shenzhen Stock Exchange interactive response to investor questions that the company's investment projects include the development of 2019-nCov monoclonal antibodies and the coVID-19 recombinant protein of the new coronavirus to present a polypeptide vaccine , repeatedly stressed the company's product injection thymus peptides as immunomodulatory drugs, and claimed that the recreational guards invested in SaiYing Capital are developing a new type of coronavirus prevention COVID-19 recombinant protein delivery polypeptide vaccine, investment Tian Guangshi is stepping up research and development for 2019-nCov monoclonal antibodies, investment in the new medical crown kit is still in the registration approval data show that Saiying Capital was jointly launched by Saisheng Pharmaceuticals and Yizhuang Biopharmaceutical Park in 2016, focusing on investment in the field of health care and life sciences, and has completed more than a dozen medical and health projects 's share price surge is strongly linked to its continued positive information about the release of new vaccines on the interactive platform But the delay in announcing the progress has ushered in the second and third largest shareholders of the huge sell-off if the closing price on June 16 is 26.61 yuan per share, the above three people reduced their total stake in the company by 16.47 million shares, the reduction is intended to cash out 438 million yuan blame disainon for the decline in performance? high net profit waist cut sales costs on the evening of June 17, Saisheng Pharmaceuticals received a letter of concern from Shenzhen Stock Exchange the Shenzhen Stock Exchange, it is required to verify whether the company's controlling shareholders, actual controllers, other major shareholders holding more than 5% of the shares, etc have traded in the company's shares in the past month for insider trading and market manipulation at the same time, the requirements combined with the company's operating situation, orders in hand, etc to explain whether the company's fundamentals change, share price increases and fundamental changes are consistent, and combined with the company's operating performance, stock price changes, and the valuation of listed companies in the same industry comparison, to fully alert investors to risk after all, the performance of Saisheng Pharmaceuticals is not optimistic Net attributable to companies fell 47.5% and 43.2% year-on-year in 2019 and the first quarter of 2020, respectively, the opposite of soaring share prices 2019, Saisheng Pharmaceuticals achieved operating income of 1.191 billion yuan, a decrease of 16.59 percent yoy, and net attributable profit of 149 million yuan, a decrease of 47.50 percent year-on-year notable, in 2018, The Pharmaceuticals' operating income increased by 90.37 percent, while net attributable profit grew by only 0.53 percent At the time, the company explained that the company's customer structure had changed as a result of the "two-vote" policy, and that the company would have to bear the costs of promoting the sale of related drugs after not increasing revenue in 2018, Saisheng Pharmaceuticals is facing a double-profit decline in 2019 and the situation is deteriorating gradually for the 2019 performance decline, Saisheng Pharmaceuticals still attributed the reason to the deepening of the reform of the medical and health system, by the state's key monitoring of drug catalogs, local medical insurance and other pharmaceutical policies, as well as market fluctuations and other factors according to the 2019 annual report of the , the company produced drug injections with forefront, acetyl helimycin tablets, acetyl heliotomycin capsules, tetracycline tablets were transferred out of the national health insurance directory; split operating income, in 2019, the income of DNA sodium injection accounted for 29.99 percent; the income of the lipalytic injection accounted for 26.91 percent; the GM1 revenue accounted for 17.85 percent; the income of the thie glycopeptide injection accounted for 16.84 percent; and the amount of the pentatoral thoracic peptide accounted for 2.91 percent drugs that have been removed from the national health insurance catalog are not the main revenue of Seisheng Pharmaceuticals , the company said, the new drug research and development projectaccelerated, research and development investment continued to grow and employee equity incentive and amortization costs increased, and other factors, also contributed to the company's operating results year-on-year decline however, of the three fees of Saisheng Pharmaceuticals, the proportion of sales costs is quite high at 763 million yuan, and the sales expense rate is increasing year by year In the last three years, the sales expense rates were 29.47 percent, 58.02 percent and 64.07 percent, respectively 2019, the company's research and development costs of 50,383.4 million yuan, although an increase of 57.80 percent year-on-year, but compared to the sales costs are still a gross increase At the same time , the capitalization of Research and Development Expenditure of Saisheng Pharmaceuticals in 2019 amounted to RMB159.405 million, accounting for 24.03% of the research and development investment, accounting for 10.80% of the current net profit; the fund-raising project can not complete a delay
1.081 billion fund raising is stranded
and one thing that can not be ignored is that Saisheng Pharmaceuticals in 2015 when the public offering of shares of the fund-raising project 's 2019 annual report shows that 553 million yuan of the public offering of shares has yet to be used The fund-raising project is basically all shelved, as of the end of 2019, "new pharmaceutical production base project" investment progress of 68.69 percent, "new cardiovascular and immunomodulating products industrialization project" investment progress of 38.83 percent and both of the projects were originally scheduled to be completed in December 2018, but were not as planned due to the limitations and effects of the long procurement cycle of air pollution prevention and control, equipment and materials After another year of extension, it is still far from being completed In addition to , the amount raised was RMB56,568.9 million, originally scheduled to be completed in December 2018, but the "marketing network construction project" has also been delayed, the investment progress is only 42.32% The reasongiven for the reasongiven for the rise in prices, labor compensation, the changing commercial real estate market, the rising cost of acquiring and renovating office buildings, the acquisition cost of meeting the requirements of the company's marketing network construction is higher, so the original expected investment acquisition office to lease mode, the investment did not meet the original schedule, the completion date changed to December 31, 2020 the repeated delay of the fund-raising project, four years of waste, also means that through the public offering of shares to raise 1,081 million yuan of funds stranded, The reasons given by Saisheng Pharmaceuticals is slightly far-fetched 2019, sales of Saisheng Pharmaceuticalproducts decreased by 22.49% YoY, and production capacity is not saturated Whether the reason for this is to deliberately slow down the progress of the fund-raising project, Seisheng Pharmaceuticals did not give an explanation June 18, Saisheng Pharmaceuticals closed at 23.60 yuan per share, down nearly 5 yuan from the previous day's high of 28.08 yuan per share Global Money Says will continue to pay attention to the future trends of the seissy pharmaceutical industry .